Related Experiment Video
Updated: May 19, 2026
08:38
Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Tacrolimus on Kimura's disease: a case report.
Shu Da-Long1, Ran Wei1, Guo Bing1
1Oral and Maxillofacial Surgery Department of the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
|September 4, 2012
Summary
Tacrolimus (FK-506) effectively treated Kimura
Area of Science:
- Immunology
- Dermatology
- Pharmacology
Background:
- Kimura's disease (KD) is a rare inflammatory condition.
- Refractory KD cases pose treatment challenges.
Observation:
- A patient with refractory KD received tacrolimus (FK-506).
- Treatment involved careful monitoring of blood concentrations.
- Dosage was adjusted over an 8-month period.
Findings:
- Salivary gland swelling resolved within one week.
- No adverse effects were observed during treatment.
- The patient remained disease-free for two years post-treatment.
Implications:
- Tacrolimus shows promise for treating Kimura's disease.
- Further research is needed to confirm long-term efficacy and safety.
- Investigating the mechanism of action is crucial.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.